We further developed a site-specific antibody targeting lactylated HNRNPA1 at K350 (Fig. 3L), which successfully detected K350 lactylation in BLCA samples (Fig. 3M–N). Here, HNRNPA1 is linked to bladder transitional cell carcinoma.